Kevin M. Brady Sells 7000 Shares of Medpace Holdings, Inc

August 8, 2023

☀️Trending News

Medpace focuses on providing a full range of clinical development services to biotechnology, pharmaceutical, and medical device companies around the world. The sale of 7000 shares of Medpace Holdings ($NASDAQ:MEDP), Inc. by Kevin M. Brady follows a recent string of acquisitions and investments by the company. In the last year, Medpace has acquired two leading contract research organizations, strengthening its offerings and increasing its global presence. The company has also recently invested in advanced clinical trial technology, such as electronic data capture and eClinical solutions, to further enhance efficiency and accuracy in its clinical trials.

Medpace Holdings, Inc. is a publicly traded company on the NASDAQ under the ticker symbol MEDP. The stock has seen steady growth over the last five years and continues to be an attractive investment opportunity for investors looking for a solid return. With its strong track record and robust growth initiatives, Medpace Holdings, Inc. is well positioned to remain a leader in the clinical research industry.

Stock Price

On Friday, Medpace Holdings, Inc (MEDPACE HOLDINGS) experienced a modest increase in stock prices. The opening price was set at $257.6 and the closing price was set at $258.8, an increase of 0.3% from the previous closing price of 258.0. This slight gain in share price occurred as Kevin M. Brady, the current Director of Medpace Holdings, Inc., sold 7000 shares of MEDPACE HOLDINGS on the open market. Although it is unknown why Brady sold these 7000 shares, it appears that the stock prices were largely unaffected by this action. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Medpace Holdings. More…

    Total Revenues Net Income Net Margin
    1.67k 268.48 15.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Medpace Holdings. More…

    Operations Investing Financing
    407.77 -34.38 -375.12
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Medpace Holdings. More…

    Total Assets Total Liabilities Book Value Per Share
    1.41k 1.02k 12.82
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Medpace Holdings are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    23.8% 34.3% 18.8%
    FCF Margin ROE ROA
    22.3% 53.3% 14.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has analyzed the financials of MEDPACE HOLDINGS and found that it has a high health score of 8/10. This indicates that it has sufficient cash flows and debt to pay off its debt and fund future operations. MEDPACE HOLDINGS also scores highly in terms of growth and profitability, but is weaker on asset and dividend. Any investor looking for a company with strong competitive advantages, stable and high revenue or earnings growth, and good health scores could be interested in MEDPACE HOLDINGS. The company’s strong performance in terms of growth and profitability makes it an attractive option for investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Medpace’s services include clinical trial management, data management, biostatistics, and medical writing. Medpace’s competitors include Icon PLC, Syneos Health Inc, and IQVIA Holdings Inc.

    – Icon PLC ($NASDAQ:ICLR)

    Icon PLC is a publicly traded company with a market capitalization of $14.59 billion as of March 2022. The company has a return on equity of 4.28%. Icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has a network of over 80 sites in 40 countries. Icon’s services include clinical research, regulatory affairs, quality management, data management, and biostatistics.

    – Syneos Health Inc ($NASDAQ:SYNH)

    Synoes Health Inc is a pharmaceutical company with a market cap of 4.81B as of 2022. The company has a Return on Equity of 9.89%. The company develops, manufactures, and sells pharmaceutical products. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company operates in the United States, Europe, and Asia.

    – IQVIA Holdings Inc ($NYSE:IQV)

    IQVIA Holdings Inc is a global healthcare company that provides market research, data, and analytics solutions to help customers drive healthcare transformation and growth. The company’s market cap as of 2022 is 33.49B, and its ROE is 19.29%. IQVIA’s customers include healthcare payers and providers, pharmaceutical and biotech companies, and government agencies. The company’s solutions help its customers drive healthcare transformation by improving patient outcomes, reducing costs, and increasing access to care.


    Additionally, analysts expect Medpace to continue growing in the coming years, with earnings projected to grow at an annual rate of 10%. Overall, Brady’s investment strategy appears to have been a prudent one.

    Recent Posts

    Leave a Comment